PhRMA perspective on population and individual bioequivalence

Journal of Clinical Pharmacology

Volumn 40, Issue 6, 2000, Pages 561-570

  Barrett, J S ^a   Batra, V ^b   Chow, A ^c   Cook, J ^d   Gould, A L ^b   Heller, A H ^e   Lo, M W ^b   Patterson, S D ^f   Smith, B P ^g   Stritar, J A ^d   Vega, J M ^b   Zariffa, N ^f  

^a DUPONT COMPANY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c R W JOHNSON PHARMACEUTICAL RES I   (United States)

^d PFIZER INC   (United States)

^e BAYER CORPORATION   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOEQUIVALENCE; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HISTORY OF MEDICINE; INDIVIDUALIZATION; MATHEMATICAL ANALYSIS; METHODOLOGY; POPULATION RESEARCH; PRACTICE GUIDELINE; REVIEW;

EID: 0033667817     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.2000.tb05980.x     Document Type: Review

References (29)

1. Guest editorial note: Bioavailability and bioequivalence
2. When are bioavailability studies required? A German proposal
3. Bioavailability and bioequivalence: Definitions and difficulties in acceptance criteria
4. Symmetric confidence intervals for bioequivalence trials
5. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
6. Consensus report from 'Bio International '89': Issues in the evaluation of bioavailability data
7. Workshop report: Evaluation of orally administered highly variable drugs and drug formulations
8. Sensitivity analysis of the effect of bioavailability or dosage form content on mean steady-state phenytoin concentrations
9. The subject-by-formulation interaction as a criterion of interchangeability of drugs
10. On population and individual bioequivalence
11. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar
12. On the assessment of variability in bioavailability/bioequivalence studies
13. Bioequivalence revisited
14. Exact inference about the within-subject variability in 2 x 2 crossover trials
15. A method for the evaluation of individual bioequivalence
16. Consideration of individual bioequivalence
17. Mean difference vs. variability reduction: Tradeoffs in aggregate measures for individual bioequivalence
18. Individual bioequivalence: Attractive in principle, difficult in practice
19. Individual bioequivalence: Has its time come?
20. Subject by formulation interaction in determinations of individual bioequivalence: Bias and prevalence
21. Case studies, practical issues and observations on population and individual bioequivalence
22. The transitivity of bioequivalence testing: Potential for drift
23. A practical approach for evaluating population and individual bioequivalence
24. On closed testing procedures with special reference to ordered analysis of variance